Download Hier steht ein Titel. Dieser Titel kann auch drei Zeilen

„ZUSAMMENARBEIT – Gesundheit“ und
„Forschung zugunsten kleiner und
mittlerer Unternehmen (KMUs)“
im 7. EU-Rahmenprogramm
Ylva Huber
Bereich Europäische und Internationale Programme
FFG – Österreichische Forschungsförderungsgesellschaft
Inhalt
• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu „Gesundheit“
• Forschung zugunsten kleiner und mittlerer Unternehmen
(KMU)
Inhalt
• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu „Gesundheit“
• Forschung zugunsten kleiner und mittlerer Unternehmen
(KMU)
Instrumente im 7. RP
7. EU-Rahmenprogramm
6. EU-Rahmenprogramm
Verbundprojekte („Collaborative
Projects)
Exzellenznetze (NoE)
Integrierte Projekte (IP)
Gezielte Forschungsprojekte (STREPs)
Exzellenznetze (NoE)
Koordinierungsmaßnahmen (CA)
Koordinierungsmaßnahmen (CA)
Unterstützungsmaßnahmen (SSA)
Unterstützungsmaßnahmen (SSA)
Unterstützung für Ausbildung und
Karriereentwicklung (Marie-Curie)
Unterstützung für Ausbildung und
Karriereentwicklung (Marie-Curie)
Einzelprojekte im ERC (Programm
Ideas)
KMU spezifische Maßnahmen
KMU spezifische Maßnahmen
Artikel 169
Artikel 169
ERA-NET und ERA-NET PLUS
ERA-NET
Gemeinsame Technologieinitiativen (JTI)
Die Ausschreibungen sind geöffnet!
rp7.ffg.at
25. Februar 2005
Präsentationstitel der FFG
6
Inhalt
• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu „Gesundheit“
• Forschung zugunsten kleiner und mittlerer Unternehmen
(KMU)
Thema 1- Gesundheit
(6.050 Mio. Euro)
Ziele:
 Verbesserung der Gesundheit der europäischen Bevölkerung
 Stärkung der europ. Industrie/Firmen
im Bereich Gesundheit
 Blick auf globale Gesundheitsfragen
(z.B. Epidemien
Schwerpunkte:
 Translationale Forschung (Grundlagenforschung  klinische
Anwendung)
 Neue Therapien (Entwicklung und Validierung)
 Methoden zur Gesundheitsförderung, Krankheitsprävention
 Diagnostische Instrumente und medizinische Technologien
 Effiziente Gesundheitssysteme
Thema 1: Gesundheit
(6.050 Mio. €)
Einreichfrist 1. Ausschreibung: 19. April 2007
Einreichfrist 2. Ausschreibung: 18. September 2007
1
Biotechnology, generic tools and technologies for human
health
2
Translating research for human health
3
Optimising the delivery of health care to European Citizens
4
Other Actions across the Health Theme
1
Biotechnology, generic tools and technologies for human
health (1)
High-throughput research




Unifying human and model organism genetic variation databases
Temporal and spatial proteomics to study biological processes relevant to
human health
Groundbreaking techniques for DNA sequencing and genotyping
2. Call:
SME-driven collaborative research projects for developing tools and technologies
for high-throughput research
Detection, Diagnosis and Monitoring






Development of a hybrid imaging system
Novel optical methodologies for detection, diagnosis and monitoring of disease or
disease-related processes
Novel targeted imaging probes for early in vivo diagnosis and/or evaluation of
response to therapy
In vivo image-guidance for cell therapy
2. Call :
Standardisation and improvement of pre-analytical procedures for in vitro
diagnostics
High throughput molecular diagnostics in individual patients for genetic
diseases with heterogeneous clinical presentation
1
Biotechnology, generic tools and technologies for human
health (2)
Predicting suitability, safety and efficacy of therapies
Thema zum Großteil durch Innovative Medicines Initiative (IMI) abgedeckt!





Novel alternative testing strategies for use in pharmaceutical discovery and
development
Bottlenecks in reduction, refinement and replacement of animal testing in
pharmaceutical discovery and development
Promotion, development, validation, acceptance and implementation of QSARs
(quantitative structure-activity relationship) for toxicology
Alternative testing strategies for the assessment of the toxicological profile of
nanoparticles used in medical diagnostics
In silico modelling for ADMET outcomes
1
Biotechnology, generic tools and technologies for human
health (3)
Innovative therapeutic approaches and interventions



Development and production of new generation antibodies
Innovative approaches for the development of vaccines for young children
Immunotherapy of human food allergies
2.Call:





Development of emerging gene therapy tools and technologies for clinical
application
Stem cell lines for cell-based therapies.
Development of stem cell culture conditions.
Stem cells for kidney regeneration.
Adding value to EU stem cell therapy research: scientific communication and
future perspectives.
Translating research for human health (1)
2
2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY
Large-scale data gathering







Networking biobanking initiatives across Europe: developing standards and
norms for existing and future human sample biobanks
Molecular epidemiological studies in existing well characterised European
(and/or other) population cohorts
Comparative studies of genetic variation in humans: towards a reference
population in Europe
Characterisation and variability of the microbial communities in the Human
Body
Structure-function analysis of membrane-transporters and channels for the
identification of potential drug target sites
High throughput analysis of lipids and lipid-protein interactions
Genome-wide association studies in mammalian non-rodent models for the
identification of genes relevant to human health and disease
Translating research for human health (2)
2
2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY
Systems biology




A system approach to eukaryotic unicellular organism biology
Modelling of T-cell activation
Fundamental approaches to stem cell differentiation
Developing an integrated in vitro, in vivo and systems biology modelling approach to
understanding apoptosis in the context of health and disease
2. call:



Multidisciplinary fundamental genomics and molecular biology approaches to study
basic biological processes relevant to health and diseases
Coordination and Support Actions in large-scale data gathering and systems biology
Traditional Chinese Medicine in post-genomic era. Specific International
Cooperation Action. Targeted region: China.
2
Translating research for human health (3)
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN
DEVELOPMENT AND AGEING
Brain and related diseases






Stroke and mechanisms underlying ischemic brain damage
Coding in neuronal assemblies
Neurobiology of anxiety disorders
Memory loss: underlying mechanisms and therapy
From basic spinal mechanisms to spinal cord disease and trauma.
Neuron-glia interactions in health and disease
2. Call:




Restorative approaches for therapy of neurodegenerative diseases.
From mood disorders to experimental models.
Neuronal mechanisms of vision and related diseases.
Childhood and adolescent mental disorders. Specific International Cooperation
Action. Target regions: Eastern Europe and Central Asia and Western Balkans.
2
Translating research for human health (4)
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN
DEVELOPMENT AND AGEING
Human Development and Ageing





Novel approaches to reconstitute normal immune function at old age.
Termination of developmental processes and their reactivation in adult life
Biomarkers of ageing.
Increasing the participation of elderly in clinical trials.
Research on human development and/or healthy ageing across the EU
2
Translating research for human health (5)
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
Anti-microbial drug resistance including fungal pathogens
2. Call:

Novel targets for drugs against Gram negative bacteria.

Host-pathogen interactions in infections by Streptococcus pneumoniae.

An integrated platform for development and clinical evaluation of point-of-care
diagnostic devices for microbial detection, antibiotic susceptibility determination
and biomarkers

Molecular epidemiology to control nosocomial and community spreading of highly
virulent multi-drug resistant strains of bacterial pathogens.

Health and economic cost of antimicrobial resistance.

Conference on genetic and biochemical tools for postgenomic physiological analysis
of Staphylococcus, in particular MRSA.
Translating research for human health (6)
2
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
HIV, AIDS, malaria and tuberculosis

HIV/AIDS Drug Discovery and Preclinical Development
Highly innovative approaches for research into host-pathogen interaction in tuberculosis
Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria and
tuberculosis and of latent tuberculosis infection (LTBI).
Addressing knowledge gaps in pregnancy malaria.
New HIV Vaccines inducing broadly-reactive neutralising antibodies.

2. Call:

Network on HIV and anti-HIV drug resistance
HIV and Hepatitis co-infection
Blocking the transmission of malaria: the mosquito vector target.
European network for study and clinical management of TB drug resistance.
Support platform for the development of PRD vaccines
Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and European
partners. (SICA, Targeted Region: India)
Coordination of European research activities with global initiatives, including Public-PrivatePartnerships (SICA; Targeted Regions: ICPC).
Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious
diseases (SICA; Targeted Regions: ICPC).











2
Translating research for human health (7)
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
Potentially new and re-emerging epidemics








Development of broadly protective influenza vaccine candidates.
Identifying immunological mechanisms of protection for influenza vaccines
Standardisation of immunological assays including surrogate markers for evaluation of new
influenza vaccines in clinical trials
Innovative point-of-care diagnostic tests for influenza.
Development of additional treatment strategies for patients suffering from highly pathogenic
influenza.
Development of pandemic influenza containment and mitigation strategies.
Supporting highly innovative inter-disciplinary research on influenza.
Influenza research in collaboration with Asian partners. (SICA, Targeted regions: Asia)
2. Call:


Strengthening research on prediction, identification, modelling and surveillance of newly
emerging infectious diseases in humans.
Definition of research needs and priorities in Europe in the area of Emerging Infectious
Epidemics.
2
Translating research for human health (8)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Cancer
•
•
•
•
•
•
•
•
Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel
diagnosis and therapy strategies.
Translating clinical ’omics’-technology (genomics, proteomics, metabolomics) into innovative
cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer
patients.
Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer.
Novel cancer screening methods.
Optimising research on end of life care of cancer patients.
Understanding and fighting metastasis.
Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy
Developing high-throughput bioassays and models for human cancers in lower species.
2. Call:
•
Innovative combination clinical trials for multimodal cancer therapy.
•
Role of inflammation in tumour initiation and progression.
•
Epidemiology of gene-environment interactions involved in carcinogenesis.
•
Translating the hypoxic tumour microenvironment.
•
ERA-NET on optimisation of the use of cancer registries for cancer research purposes
•
Studying cancer aetiology in Latin America. (SICA)
2
Translating research for human health 9)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Cardiovascular Disease



Molecular basis of the inflammatory response and associated vascular remodelling in
arteriosclerosis.
Vascular remodelling in aneurysmal disease.
Combating stroke.
2. Call:

Congenital pathologies affecting the heart.

Cell therapies for the treatment of heart ischemia.

Organ imaging in CVD.

Integrating pharmacogenomic approaches into the treatment of CVD.
2
Translating research for human health 10)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Diabetes and Obesity

Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention.
Combined forms of diabetes in children.

Insulin resistance as a key factor in the development of diabetes and metabolic syndrome.

Pathophysiological mechanisms related to excess fat.

A road-map for diabetes research.

2. Call:




Nutritional signals and the development of new diabetes/obesity therapeutic agents.
Markers and treatment for diabetic neuropathy complications.
Geno- and phenotypical differentiation of type 2 subjects and monogenic subjects.
Use of beta cell imaging in diabetes mellitus.
2
Translating research for human health 11)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Rare Diseases


Natural course and pathophysiology of rare diseases.
Research capacity-building in the field of rare diseases.
Other Chronic Diseases
Osteoarthritis.

Inflammatory bowel disease.

Osteoporosis: signalling pathways in bone formation and homeostasis.

Genetic factors of Osteoporosis.

Intervertebral disc degeneration: prevention and repair.

Innovative concepts in chronic obstructive pulmonary disease pathogenesis (COPD).

Hearing impairment and degeneration.

Impairment of touch and proprioception at old age.

Visual impairment and degeneration.
2. Call:

Understanding and combating age-related muscle weakness.

Translational research aiming for a treatment of urinary incontinence.

Early processes in the pathogenesis of chronic inflammatory diseases.

3
Optimising the delivery of health care to European Citizens (1)
Translating clinical research into clinical practice including better use of
medicines, and appropriate use of behavioural and organisational
interventions and health therapies and technologies
2.call:







Implementation of research into healthcare practice
Self-medication and patient safety
Patient Safety Research Network
Improving clinical decision making
Better use of medicines.
Continuity of clinical care.
Patient self-management of chronic disease.
Quality, solidarity and sustainability of health systems
2.call:








Evaluation of disease management programmes
Health systems and long term care of the elderly
Mobility of health professionals
Health care human resource planning in nursing.
Clinician working time and patient safety.
Health outcome measures and population ageing.
Trends of population health
European system of Diagnosis-related groups (DRG)
3
Optimising the delivery of health care to European Citizens (2)
Enhanced health promotion and disease prevention
2.call:





Promoting healthy behaviour in children and adolescents
Interventions addressing the gradient of health inequalities
Public health interventions addressing the abuse of alcohol.
Evaluation of suicide prevention strategies across and within European countries.
Improve vaccination coverage
Horizontal Coordination and Support Actions across “Optimising the Delivery
of Health Care to European Citizens
2.call:








Disease networks of centres of reference.
Effectiveness of health investments.
Patient mobility and access to information.
Brokering research into policy.
A road-map for ageing research.
Health Services Research conference
Mental health research conference.
Public Health intervention research conference
3
Optimising the delivery of health care to European Citizens (3)
Specific International Cooperation Actions for Health System Research
2.call:

Epidemiological investigations into long-term trends of population health as
consequence of socio-economic transitions, including life-style induced
health problems. SICA (Mediterranean Partner countries, Russia, Eastern
European and Central Asia)

Universal and equitable access to health care and health financing. SICA
(MCP, ACP, Asia and Latin America)

Health care intervention research – optimising hospital care. SICA (Western
Balkans.)

Health care intervention research – improving pre-natal and maternal care.
SICA (ACP and Mediterranean Partner Countries)
4
Other Actions across the Health Theme
Coordination and Support Actions across the Theme
•
•
•
•
•
Reinforcing the network of National Contact Points (NCP) for the Seventh Framework
Programme under Health Theme by promoting transnational co-operation.)
Promoting participation of high-technology research intensive SMEs, operating in the
biomedical engineering and other medical technology sectors´relevant to Health Theme.
Assessment and valorisation of project outcome for hightechnology and research intensive
SME participating to Framework Programmes of Research in the healthcare sector.
Science communication actions.
Initiatives to foster dialogue and debate on health research issues of interest to the
public.
•
Studies on the impact of EU legislation on health research and related developments and
applications.
2.call:
•
Promotion and facilitation of international cooperation in areas relevant to the objectives of
this theme. (SICA, ICPC)
Responding to EU policy needs (2.call)

Paediatric medicinal products, Drug safety research, Living and work conditions,
Health statistics, Tobacco Control
Technologieplattformen und
Gemeinsame Technologieinitiativen
• Mobilisierung europäischer Ressourcen im Bereich Forschung,
technologische Entwicklung und Innovation durch Zusammenbringen aller
Akteure eines definierten Forschungsbereiches (Industrie, KMU,
Universitäten, Endverbraucher)
• Industriegetrieben
• Gemeinsame Definition und Erstellung einer strategischen
Forschungsagenda (mittel- bis langfristig)
= Input zur Entwicklung der thematischen Programme im 7. RP
• Einige wenige werden als Gemeinsame Technologieinitiativen (Joint
Technology Initiatives) etabliert
• Neuer Weg zur Realisierung von public-private partnerships auf EUEbene mit definierter rechtlicher Struktur
Example „Innovative Medicines“ en route to a „Joint Technology Initiative“
 Accelerated Development of safe and more effective medicines
 Revitalization of the the biopharmaceutical research and development (R&D)
environment for Europe to become more competitive
 Improving the collaboration between all relevant actors from public and
private organisations (public-private partnerships)

Draft and Implementation of a European Research Agenda:
Second version of the Strategic Research Agenda published recently
 First Calls
expected for end of 2007/beginning of 2008
 http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed
 http://rp7.ffg.at/RP7.aspx_param_target_is_116120.v.aspx
« Innovative Medicines »
2. version of the « Strategic Research Agenda »:
4 main topics:

Safety:
Early safety evaluation and risk assessment, creation of a European
Centre for Drug Safety

Efficacy:
Predictive pharmacology, biomarker identification and validation, patient
recruitment and risk assessment

Knowledge Management:
New technologies to control and analyse enormous quantities of
information in an integrative and predictive way

Education and Training:
Bridge gaps in expertise required to strengthen the biopharmaceutical
R&D process, creation of a European Medicines Research Academy
Technologieplattform
« Innovative Medicines »

Contact in Austria:
Univ. Prof. Dr. Hans Georg Eichler,
Vice Rector of the Medical University in Vienna
[email protected]
Relevante Themen der 1.
Ausschreibungen aus anderen Bereichen
Food, Agriculture, Fisheries and Biotechnology:
e.g. Fork to farm: Food (including seafood), health and well being
Information and Communication Technologies:
Objective ICT-2007.5.3: Virtual Physiological Human
Nanosciences, Nanotechnologies, Materials and new Production
Technologies:
„Creation of a critical and commented database on the health,
safety and environmental impact of nanoparticles“
„Substantial innovation in the European medical industry: development of
nanotechnology-based systems for in-vivo diagnosis and therapy (in
Coordination with topic HEALTH-2007-2.4.1-7 and HEALTH-2007-1.2-3 in
Theme 1 "Health")
Environment: Environment and Health
Security: Topic SEC-2007-1.3-05 Water distribution surveillance; Critical Infrastructure
Protection
Inhalt
• Das 7. Rahmenprogramm im Überblick
• Themen der ersten Ausschreibungen zu „Gesundheit“
• Forschung zugunsten kleiner und mittlerer Unternehmen
(KMU)
Zusammenarbeit zwischen Industrie
und F&E-Dienstleistern
• Forschung zugunsten von Kleinen und Mittleren Unternehmen
(KMUs)
• Forschung zugunsten von KMU-Verbänden
25. Februar 2005
Präsentationstitel der FFG
34
Kennzeichen
• Themen: Bottom up –Ansatz (gesamtes Feld der Wissenschaft &
Technologie)
• KMUs/KMU-Verbände lagern Forschung & technologische
Entwicklung aus
• Flexibilität bezüglich der intellectual property rights
25. Februar 2005
Präsentationstitel der FFG
35
Aktivitäten
• Forschungs- und technologische Entwicklungsaktivitäten
• Demonstrationsaktivitäten
• Andere Aktivitäten (Trainings, dissemination activities)
• Management-Aktivitäten
25. Februar 2005
Präsentationstitel der FFG
36
Research for SMEs
Project participation scheme
RTDperformers
Industry
at least 3 SMEs from
at least 3 countries (MS, AS)
25. Februar 2005
at least 2
universities
research centres
industrial companies
research performing SMEs
Präsentationstitel der FFG
37
Research for SMEs/
SME-Associations
Research for SMEs
Research for SME
associations
Duration
1 - 2 years
2 - 3 years
Number of partners
5 - 10
10 -15
Total budget*
€ 0.5 – 1.5 Million
€ 1.5 – 4 Million
Activities
R&D, demonstration,
management, other
activities
R&D, demonstration,
management, other activities
* Share of R&D carried out by RTD performers :
≥ 60%
25. Februar 2005
Präsentationstitel der FFG
Source: European Commission
39
Einreichfristen:
•
•
•
•
•
Research for SMEs:
FP7-SME-2007-1
Einreichfrist: 4.September 200
Research for SME Associations:
FP7-SME-2007-2
Einreichfrist: 1. Juni
2007
•
Kontakt: Dr. Ines Haberl, [email protected]
•
•
http://rp7.ffg.at/RP7.aspx
http://cordis.europa.eu/en/home.html
25. Februar 2005
Präsentationstitel der FFG
40
Wichtige Dokumente zur Vorbereitung:




Arbeitsprogramme + Annexes
Guide for Applicants
Rules for Participation
Model Grant Agreement
 Leitfaden/Formular für Anbahnungsfinanzierung:
rp7.ffg.at -> „Services der FFG“
Page 41/45
Y.Huber / FFG-EIP
Kontaktieren Sie uns!
Ihre Ansprechpartner für Life Sciences in der FFG/
Bereich Europäische und Internationale
Programme
Mag. Birgit Steininger
Leiterin des Referats für Biowissenschaften,
Nationale Kontaktstelle für Lebensmittel, Landwirtschaft und Biotechnologie (DW 4101)
[email protected]
Dr. Ylva Huber
Nationale Kontaktstelle für Gesundheit (DW 4102)
[email protected]
Dr. Ines Haberl
Nationale Kontaktstelle für KMUs (DW 4103)
[email protected]
e-mail: [email protected], Tel: +43/57755-Durchwahl
Page 42/45
Y.Huber / FFG-EIP
Vielen Dank für Ihre Aufmerksamkeit
&
viel Erfolg für Ihre Projekte
im 7. Rahmenprogramm!